tiprankstipranks

Context Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar downgraded Context Therapeutics to Neutral from Buy without a price target after the company said it is discontinuing development of its lead asset, Onaxr, and focusing resources on CTIM-76. The analyst views the news as disappointing given efficacy data in the OATH study "were encouraging." The firm says Context no longer has any clinical programs.

Confident Investing Starts Here:

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CNTX:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue